NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

• NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), daratumumab-dexamethasone (Dd), or nirogacestat (Niro) in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed.

Sponsor

TeneoOne Inc.

Abbvie

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT05259839

Official Title: A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

First Posted : March 2, 2022

Click here to see details on ClinicalTrials.gov

---

Drug: ABBV-383

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Pomalidomide

Drug: Nirogacestat

Drug: Daratumumab

ABBV-383 (formerly TNB-383B)

TNB-383B

anti-alpha BCMA/anti-alpha CD3 T-cell engaging bispecific antibody TNB-383B

---

* TNB-383B

* anti-BCMA x aCD3 T-BsAb TNB-383B

* anti-BCMA x aCD3 T-cell engaging bispecific antibody TNB-383B

---

Jun 24, 2021, 08:00 ET: AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

Click here for details

---

Locations

United States, Arkansas

United States, Florida

United States, Maryland

United States, Michigan

United States, Montana

United States, New Jersey

United States, North Carolina

United States, Texas

United States, Utah

United States, Washington

Europe

Germany

Italy

Spain

Poland